PULIKE(SH:603566)2018-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 15.52% to CNY 38,551,260.14 year-on-year[9] - Operating revenue rose by 8.77% to CNY 143,820,632.50 compared to the same period last year[9] - Basic earnings per share increased by 20.00% to CNY 0.12[9] - Total operating revenue for Q1 2018 was CNY 143,820,632.50, an increase of 8.7% from CNY 132,228,870.11 in the same period last year[27] - Net profit for Q1 2018 reached CNY 38,551,260.14, representing a 15.5% increase compared to CNY 33,371,956.54 in Q1 2017[28] - Total profit for Q1 2018 was CNY 44,358,843.71, an increase of 15.5% from CNY 38,460,737.68 in Q1 2017[28] Asset and Liability Management - Total assets increased by 1.76% to CNY 1,836,925,830.90 compared to the end of the previous year[9] - The company's current assets totaled CNY 1,178,570,353.07, up from CNY 1,151,850,409.31 at the start of the year, indicating an increase of about 2.3%[19] - Total liabilities decreased to CNY 228,585,028.46 from CNY 236,271,421.26, marking a reduction of approximately 3.2%[21] - The company's equity attributable to shareholders rose to CNY 1,608,340,802.44 from CNY 1,568,839,814.83, reflecting an increase of about 2.0%[21] - Total liabilities as of the end of Q1 2018 were CNY 183,571,071.94, a slight decrease from CNY 185,667,438.29 at the end of the previous year[28] - Total equity increased to CNY 1,584,809,332.77 in Q1 2018, compared to CNY 1,551,381,624.20 in the same period last year, reflecting a growth of 2.1%[28] Revenue Sources - Revenue from pig vaccines (market sales) surged by 55.20% to CNY 45,004,374.68[12] - Revenue from poultry vaccines and antibodies increased by 15.68% to CNY 45,843,451.37[12] Cash Flow Analysis - Cash flow from operating activities showed a net outflow of CNY 12,636,127.88, worsening by 102.20% compared to the previous year[9] - Cash flow from operating activities was CNY 93,733,018.71, down from CNY 99,998,502.16 in Q1 2017[33] - The net cash flow from operating activities was -12,636,127.88 RMB, compared to -6,249,219.45 RMB in the previous period, indicating a decline in operational performance[34] - The total cash inflow from operating activities was 101,205,292.86 RMB, slightly lower than 106,079,059.19 RMB in the previous period, showing a minor decline in operational cash generation[34] - Cash outflow from operating activities was 113,841,420.74 RMB, compared to 112,328,278.64 RMB in the previous period, indicating increased operational expenses[34] Investment Activities - The company reported an investment income of CNY 6,073,793.34, significantly higher than CNY 2,109,612.68 in the previous year[28] - The company received 585,000,000.00 RMB from investment recoveries, a substantial increase from 220,000,000.00 RMB in the previous period, highlighting successful investment strategies[37] - The total cash outflow from investment activities was 605,234,857.80 RMB, significantly higher than 278,854,272.50 RMB in the previous period, indicating aggressive investment spending[34] Other Financial Metrics - The weighted average return on equity increased by 0.17 percentage points to 2.40%[9] - Accounts receivable rose by 40.18% to CNY 152,069,345.07 due to increased product sales[14] - Prepayments increased by 298.86% to CNY 7,407,091.36 mainly due to prepayments for technology transfer fees and R&D materials[14] - Cash and cash equivalents decreased to CNY 238,592,605.78 from CNY 263,484,603.85, a decline of approximately 9.4%[19] - The company's inventory stood at CNY 72,061,112.36, slightly up from CNY 71,088,934.60, showing a marginal increase of about 1.4%[19] - The non-current assets totaled CNY 658,355,477.83, slightly up from CNY 653,260,826.78, reflecting a growth of about 0.4%[20] - The company's total liabilities to total assets ratio improved to approximately 12.4% from 13.1%, indicating a stronger financial position[21]